• If you are wondering whether Doximity's current share price lines up with its underlying worth, you are not alone. This article unpacks what the numbers are actually saying about value.
• The stock closed at US$24.37, with returns of a 3.8% decline over 7 days, a 6.1% decline over 30 days, a 43.7% decline year to date, and a 61.5% decline over the past year. This naturally raises questions about whether risk perceptions or growth expectations have shifted.
• Recent news coverage around Doximity has largely focused on its role as a digital platform for medical professionals and on how investors are reassessing growth-oriented technology names. That context has kept attention on how quickly the business model can translate into sustainable cash flows and whether the current share price already reflects those expectations.
• On our valuation checks, Doximity scores 5 out of 6, giving it a valuation score of 5. Next, we will walk through the standard valuation approaches before finishing with a broader framework that can help you make more sense of that score.

Approach 1: Doximity Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a business could be worth by projecting its future cash flows and then discounting those back to today, using a required rate of return. It is essentially asking what those future dollars are worth in today's terms.

For Doximity, the 2 Stage Free Cash Flow to Equity model starts with last twelve months free cash flow of about $306.6 million. Analysts have provided several years of projections, with Simply Wall St extending those forecasts out to 2035. Within this, free cash flow for 2030 is projected at $447.4 million, with ten year forecasts ranging from about $306.1 million in 2026 to $602.9 million in 2035, all in $ and then discounted back to present value.

Adding those discounted cash flows together gives an estimated intrinsic value of US$46.67 per share. Against the recent share price of US$24.37, the model suggests the stock trades at a 47.8% discount, which on this framework indicates a materially undervalued reading.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Doximity is undervalued by 47.8%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Approach 2: Doximity Price vs Earnings

For a profitable company like Doximity, the P/E ratio is a useful way to relate what you pay for each share to the earnings that business is currently generating. Investors usually accept a higher P/E when they expect stronger growth or see lower risk, and a lower P/E when growth expectations are more modest or risks feel higher.

Doximity is trading on a P/E of 18.8x. That sits below the Healthcare Services industry average of 28.9x and also below the peer average of 32.8x that Simply Wall St uses for comparison. On the surface, that suggests the market is pricing Doximity at a discount to many peers in its space.

Simply Wall St goes a step further with its Fair Ratio, which is the P/E level it would expect given factors such as Doximity's earnings growth profile, industry, profit margins, market cap and specific risks. This Fair Ratio for Doximity is 20.4x. Because it is tailored to the company, it offers a more targeted benchmark than broad industry or peer averages. Comparing 18.8x to the Fair Ratio of 20.4x points to the shares trading below that company specific benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Doximity Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. Narratives let you attach a clear story about Doximity to the numbers you see by linking your view of its business, your assumptions for future revenue, earnings and margins, and the Fair Value those assumptions imply. All of this is available within an easy tool on Simply Wall St's Community page that updates as new earnings or news arrive and helps you compare Fair Value to the current price. This allows you to judge for yourself whether Doximity looks more like the bullish case with a Fair Value of about US$56, the cautious case closer to US$25, or something in between like the US$63.57 view, depending on which story you think best reflects the company.

Do you think there's more to the story for Doximity? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.